FrancophonIA/ELRC3.0 huggingface dataset:
English: Urorec 4 mg are yellow, opaque, hard gelatin capsules, size 3 (approximately 15.9 x 5.8 mm).
Croatian: Urorec 4 mg su žute, neprozirne tvrde želatinske kapsule, veličine 3 (približno 15,9 x 5,8 mm).
English: Deutschland Recordati Pharma GmbH Tel: + 49 731 70470
Croatian: Recordati Pharma GmbH Tel: + 49 731 70470
English: Recordati Hellas Pharmaceuticals A.E. Τηλ: + 30 210-6773822
Croatian: Τηλ: + 30 210-6773822
English: What Urorec is used for
Croatian: Za što se Urorec koristi
English: Urorec is selective for the receptors located in the prostate, bladder and urethra.
Croatian: Urorec se selektivno veže za receptore koji se nalaze u prostati, mokraćnom mjehuru i mokraćnoj cijevi.
English: The recommended dose is one capsule of Urorec 8 mg per day by oral administration.
Croatian: Preporučena doza je jedna kapsula lijeka Urorec od 8 mg na dan primjenom kroz usta.
English: G.C.
Croatian: C.
English: SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN Keep out of the sight and reach of children.
Croatian: Kako čuvati Urorec Lijek čuvajte izvan pogleda i dohvata djece.
English: Papaloisou Ltd. Τηλ: + 357 22 49 03 05
Croatian: Τηλ: + 357 22 49 03 05
English: What Urorec looks like and contents of the pack Urorec 8 mg are white, opaque, hard gelatin capsules, size 0 (approximately 21.7 x 7.6 mm).
Croatian: Urorec 8 mg su bijele, neprozirne, tvrde želatinske kapsule, veličine 0 (približno 21,7 x 7,6 mm).
English: Urorec 4 mg and 8 mg hard capsules
Croatian: Urorec 4 mg i 8 mg tvrde kapsule
English: Raheens East
Croatian: Raheens East Ringaskiddy Co.
English: België/Belgique/Belgien Recordati Ireland Ltd.
Croatian: België/Belgique/Belgien
English: What Urorec is and what it is used for What you need to know before you take Urorec How to take Urorec
Croatian: Što je Urorec i za što se koristi Što je Urorec
English: Tel: +385 1 63 11 833
Croatian: PharmaSwiss d.o.o. Tel: +385 1 63 11 833
English: Urorec 4 mg hard capsules Each hard capsule contains 4 mg silodosin.
Croatian: Urorec 4 mg tvrde kapsule Jedna tvrda kapsula sadrži 4 mg silodozina.
English: Urorec 8 mg hard capsules Urorec 4 mg hard capsules
Croatian: Urorec 4 mg tvrde kapsule Urorec 8 mg tvrde kapsule
English: Elimination Following oral administration of 14C-labelled silodosin, the recovery of radioactivity after 7 days was approximately 33.5% in urine and 54.9% in faeces.
Croatian: 33,5 % radioaktivnosti, a u stolici približno 54,9 %.
English: Urorec 4 mg hard capsules
Croatian: Urorec 4 mg tvrde kapsule
English: Urorec 8 mg hard capsules
Croatian: Urorec 8 mg tvrde kapsule
English: In patients with severe renal impairment administration of Urorec is not recommended.
Croatian: U bolesnika s teškim oštećenjem funkcije bubrega ne preporučuje se primjena lijeka Urorec.
English: NAME OF THE MEDICINAL PRODUCT Urorec 4 mg hard capsules silodosin
Croatian: Urorec 4 mg tvrde kapsule silodozin
English: Focused Pharma Ltd. Tel: + 356 79426930
Croatian: Tel: + 356 79426930
English: NAME OF THE MEDICINAL PRODUCT Urorec 8 mg hard capsules silodosin
Croatian: Urorec 8 mg tvrde kapsule silodozin
English: How to store Urorec
Croatian: Moguće nuspojave Kako čuvati Urorec
English: B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to medical prescription.
Croatian: PRILOG II. A. PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA U PROMET B. UVJETI ILI OGRANIČENJA VEZANI UZ OPSKRBU I PRIMJENU C. OSTALI UVJETI I ZAHTJEVI ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET
English: What Urorec contains
Croatian: Kako Urorec izgleda i sadržaj pakiranja
English: Perjeta is used in the following situations:
Croatian: Perjeta se primjenjuje u sljedećim situacijama:
English: The full EPAR for Perjeta can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Perjeta nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The recommended first dose is 840 mg given over one hour.
Croatian: Preporučena prva doza iznosi 840 mg i daje se tijekom sat vremena.
English: What is Perjeta and what is it used for?
Croatian: Što je Perjeta i za što se koristi?
English: Perjeta received a marketing authorisation valid throughout the European Union on 4 March 2013.
Croatian: Lijek Perjeta dobio je odobrenje za stavljanje u promet koje je na snazi u Europskoj uniji od 4. ožujka 2013.
English: This is followed by a dose of 420 mg every three weeks, with each dose given over half an hour to one hour.
Croatian: Nakon toga slijedi doza od 420 mg svaka tri tjedna, s time da se svaka doza primjenjuje tijekom razdoblja od pola sata do sat vremena.
English: It also activates cells of the immune system (the body's natural defences), which then kill the cancer cells.
Croatian: Također aktivira djelovanje stanica imunosnog sustava (prirodnog obrambenog sustava tijela), koje zatim ubijaju stanice raka.
English: What measures are being taken to ensure the safe and effective use of Perjeta?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Perjeta?
English: Treatment with Perjeta should be interrupted or stopped permanently if the patient gets certain side effects.
Croatian: Terapiju lijekom Perjeta treba prekinuti ili trajno obustaviti ako bolesnici dobiju određene nuspojave.
English: The most common severe side effect (affecting more than 1 in 10 people) is neutropenia, with or without fever.
Croatian: Najčešća teška nuspojava (koja se može pojaviti u više od 1 na 10 osoba) jest neutropenija, sa ili bez vrućice.
English: Patients treated with Perjeta lived for 18.5 months without their disease getting worse, compared with 12.4 months for patients given placebo.
Croatian: Bolesnici liječeni lijekom Perjeta živjeli su 18,5 mjeseci bez pogoršanja bolesti, u usporedbi s 12,4 mjeseca u bolesnika koji su primali placebo.
English: Why is Perjeta authorised in the EU?
Croatian: Zašto je lijek Perjeta odobren u EU-u?
English: What are the risks associated with Perjeta?
Croatian: Koji su rizici povezani s lijekom Perjeta?
English: The Agency considered that, despite the side effects of Perjeta, the overall safety profile was acceptable.
Croatian: Agencija je smatrala da je, usprkos nuspojavama zabilježenima pri primjeni lijeka Perjeta, ukupan sigurnosni profil prihvatljiv.
English: For more information about using Perjeta, see the package leaflet or contact a doctor or pharmacist.
Croatian: Za više informacija o primjeni lijeka Perjeta vidjeti uputu o lijeku ili se obratite liječniku ili ljekarniku.
English: An overview of Perjeta and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Perjeta i zašto je odobren u EU-u
English: Side effects reported with Perjeta are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Perjeta pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: The main measure of effectiveness was progression-free survival (how long the patients lived without their disease getting worse).
Croatian: Glavna mjera učinkovitosti bilo je preživljenje bez progresije bolesti (vrijeme koje su bolesnici proživjeli bez pogoršanja bolesti).
English: Other information about Perjeta
Croatian: Ostale informacije o lijeku Perjeta
English: As for all medicines, data on the use of Perjeta are continuously monitored.
Croatian: Kao za sve lijekove, podatci o primjeni lijeka Perjeta kontinuirano se prate.
English: Perjeta was shown to be of benefit in patients whose cancer was at a high risk of coming back: after 4 years, the disease had not spread in 90% of patients with ‘node-positive' cancer treated with Perjeta compared with 87% of those receiving placebo; for those with ‘hormone-receptor negative' cancer, this figure was 91% of patients treated with Perjeta, and 89% of patients given placebo.
Croatian: Dokazano je da lijek Perjeta stvara koristi za bolesnike kod kojih postoji značajan rizik od ponovne pojave raka: nakon 4 godine bolest se nije proširila u 90 % bolesnika s rakom s „pozitivnim limfnim čvorovima” koji su liječeni lijekom Perjeta u usporedbi s 87 % bolesnika koji su primali placebo; za bolesnike s rakom s „negativnim hormonskim receptorima”, ova brojka iznosi 91 % bolesnika liječenih lijekom Perjeta te 89 % bolesnika koji su primali placebo.
English: Patients were treated until their disease got worse or the side effects of treatment became unmanageable.
Croatian: Bolesnici su liječeni sve dok se njihova bolest nije pogoršala ili dok se nuspojave terapije više nisu mogle kontrolirati.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Perjeta have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Perjeta također se nalaze u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: The most common side effects (affecting more than 3 in 10 people) with Perjeta when given with trastuzumab and chemotherapy are neutropenia (low levels of neutrophils, a type of white blood cell important for fighting infections), diarrhoea, nausea (feeling sick), vomiting, hair loss and tiredness.
Croatian: Najčešće nuspojave (koje se mogu javiti u više od 3 na 10 osoba) povezane s lijekom Perjeta kada se primjenjuje s trastuzumabom i lijekovima za kemoterapiju jesu neutropenija (niske razine neutrofila, vrste bijelih krvnih stanica važnih za borbu protiv infekcija), proljev, mučnina (osjećaj slabosti), proljev, gubitak kose i umor.
English: Perjeta is given by infusion (drip) into a vein.
Croatian: Lijek Perjeta daje se intravenskom infuzijom (drip).
English: The studies looked at how many patients responded to treatment (i.e. patients who had no cancer cells in the breast after surgery).
Croatian: U ispitivanjima se utvrđivalo koliko je bolesnika odgovorilo na terapiju (tj. nisu imali stanice raka u dojci nakon kirurškog zahvata).
English: Perjeta can only be obtained with a prescription and treatment should be started under the supervision of a doctor who is experienced in using cancer medicines and in a hospital setting where resuscitation equipment is available.
Croatian: Perjeta se izdaje samo na liječnički recept, a liječenje se smije započeti samo pod nadzorom liječnika s iskustvom u primjeni lijekova protiv raka, i to u bolničkim uvjetima u kojima je dostupna oprema za oživljavanje.
English: In these studies, Perjeta was given with trastuzumab or chemotherapy or both.
Croatian: U tim se ispitivanjima lijek Perjeta primjenjivao zajedno s trastuzumabom ili kemoterapijom ili s oboje.
English: HER2-positive breast cancer is an aggressive form of breast cancer which occurs in around one in five cases.
Croatian: HER2 pozitivan rak dojke agresivan je oblik raka dojke koji se javlja u otprilike jednom na pet slučajeva.
English: The European Medicines Agency considered that Perjeta has been shown to benefit patients with metastatic cancer by extending the amount of time patients lived without their disease getting worse as well as how long they lived.
Croatian: Europska agencija za lijekove zaključila je kako je lijek Perjeta pokazao koristi u bolesnika s metastatskim rakom tako što je produžio vrijeme tijekom kojeg su bolesnici živjeli bez pogoršanja bolesti te je također produžio njihov život.
English: How is Perjeta used?
Croatian: Kako se Perjeta koristi?
English: Perjeta has also been shown to improve the outcome of patients with earlier stages of breast cancer, when used with trastuzumab and chemotherapy.
Croatian: Također je utvrđeno da Perjeta poboljšava ishod bolesnika s ranijim stadijima raka dojke, kada se koristio s trastuzumabom i lijekovima za kemoterapiju.
English: In these cases, Perjeta is used with trastuzumab and docetaxel (other cancer medicines);
Croatian: U tim se slučajevima Perjeta primjenjuje zajedno s trastuzumabom i docetakselom (drugim lijekovima protiv raka);
English: • treatment of metastatic breast cancer (cancer that has spread to other parts of the body) that has not already been treated with chemotherapy medicines or medicines designed to target HER2, or for breast cancer that has come back locally after treatment and cannot be removed by surgery.
Croatian: • za liječenje metastatskog raka dojke (raka koji se proširio na druge dijelove tijela) koji prethodno nije liječen lijekovima za kemoterapiju ili lijekovima usmjerenima na liječenje HER2 ili za liječenje raka dojke koji se vratio nakon terapije i ne može se ukloniti kirurškom zahvatom.
English: A fourth ongoing study compared Perjeta with placebo (both given with trastuzumab and chemotherapy) in 4,805 women with early breast cancer who had had surgery to remove the cancer.
Croatian: U četvrtom ispitivanju, koje je u tijeku, lijek Perjeta uspoređen je s placebom (oboje se primjenjuje s trastuzumabom i lijekovima za kemoterapiju) u 4 805 žena s ranim rakom dojke koje su bile podvrgnute kirurškom zahvatu radi uklanjanja raka.
English: Perjeta is a cancer medicine for treating adults with ‘HER2-positive' breast cancer (where a protein called HER2 is found on the cancer cells).
Croatian: Perjeta je lijek za liječenje odraslih osoba koje boluju od „HER2-pozitivnog” raka dojke (u kojem se na stanicama raka pojavljuje protein koji se naziva HER2).
English: Perjeta has also been studied in two main studies involving a total of 642 patients with earlier stages of breast cancer who were to undergo surgery.
Croatian: Lijek Perjeta također je ispitan u dvama glavnim ispitivanjima kojima je obuhvaćeno ukupno 642 bolesnika s rakom dojke u ranijim stadijima koji su trebali biti podvrgnuti kirurškom zahvatu.
English: In the first study, 46% of the patients treated with Perjeta plus trastuzumab and docetaxel responded to treatment, compared with 29% of patients who received trastuzumab and docetaxel alone.
Croatian: U prvom ispitivanju 46 % bolesnika liječenih lijekom Perjeta u kombinaciji s trastuzumabom i docetakselom odgovorilo je na terapiju, u usporedbi s 29 % bolesnika koji su primili monoterapiju trastuzumabom i docetakselom.
English: What benefits of Perjeta have been shown in studies?
Croatian: Koje su koristi od lijeka Perjeta utvrđene u ispitivanjima?
English: pertuzumab stops HER2 producing signals that cause the cancer cells to grow.
Croatian: Vezivanjem na HER2, pertuzumab zaustavlja proizvodnju HER2 signala koji uzrokuju rast stanica raka.
English: The effects of Perjeta were compared with placebo (a dummy treatment) when given together with other cancer medicines (trastuzumab and docetaxel).
Croatian: Djelovanje lijeka Perjeta uspoređeno je s placebom (prividnim liječenjem) ako se lijek primijenio zajedno s drugim lijekovima protiv raka (trastuzumabom i docetakselom).
English: Perjeta has been studied in one main study involving 808 adults with previously untreated HER2positive metastatic breast cancer.
Croatian: Lijek Perjeta ispitan je u jednom glavnom ispitivanju koje je obuhvatilo 808 odraslih osoba s HER2 pozitivnim metastatskim rakom dojke koje prethodno nisu bile liječene.
English: The company that markets Perjeta will carry out a study to assess the effects of using Perjeta and trastuzumab together with a type of cancer medicines called taxanes, in previously untreated patients with HER2-positive metastatic or locally advanced breast cancer.
Croatian: Tvrtka koja stavlja u promet lijek Perjeta provest će ispitivanje kojim će procijeniti učinke istodobne primjene lijeka Perjeta i trastuzumaba zajedno s vrstom lijekova za liječenje raka naziva taksani, u bolesnika s HER2 pozitivnim metastatskim rakom dojke ili lokalno uznapredovalim rakom dojke, koji prethodno nisu bili liječeni.
English: For the full list of all side effects and restrictions with Perjeta, see the package leaflet.
Croatian: Potpuni popis svih nuspojava i ograničenja pri primjeni lijeka Perjeta potražite u uputi o lijeku.
English: It considered that this would provide an additional benefit when added to other medicines for HER2-positive cancer, notably trastuzumab.
Croatian: Agencija je zaključila kako će se pružiti dodatne koristi ako se lijek doda drugim lijekovima za liječenje HER2 pozitivnog raka, i to trastuzumabu.
English: • treatment of locally advanced, inflammatory or early-stage breast cancer at high risk of coming back, in combination with trastuzumab and chemotherapy, before the patient undergoes surgery;
Croatian: • liječenje lokalno uznapredovalog, upalnog raka dojke ili raka dojke u ranoj fazi kod kojeg postoji značajan rizik od ponovne pojave raka, u kombinaciji s trastuzumabom i lijekovima za kemoterapiju, prije podvrgavanja bolesnika kirurškom zahvatu;
English: The active substance in Perjeta, pertuzumab, is a monoclonal antibody, a type of protein that has been designed to attach to HER2, a protein found on HER2-positive cancer cells.
Croatian: Djelatna tvar lijeka Perjeta, pertuzumab, monoklonsko je protutijelo, tj. vrsta proteina koja je osmišljena kako bi se vezala na HER2, protein koji se nalazi na stanicama raka koje su HER2 pozitivne.
English: • treatment of early breast cancer at high risk of coming back, in combination with trastuzumab and chemotherapy, after the patient has had surgery.
Croatian: • liječenje raka dojke u ranoj fazi kod kojeg postoji značaj rizik od ponovne pojave raka, u kombinaciji s trastuzumabom i kemoterapijom, nakon podvrgavanja bolesnika kirurškom zahvatu.
English: Response to treatment in the second study ranged from 57% to 66% where Perjeta was given with trastuzumab and chemotherapy medicines.
Croatian: Odgovor na terapiju u drugom ispitivanju, kada se lijek Perjeta primjenjivao s trastuzumabom i lijekovima za kemoterapiju, bio je u rasponu od 57 % do
English: How does Perjeta work?
Croatian: Kako djeluje Perjeta?
English: The full EPAR for Reagila can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Reagila nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The recommended starting dose is 1.5 mg once a day.
Croatian: Preporučena početna doza je 1,5 mg jednom na dan.
English: Side effects are mostly mild or moderate.
Croatian: Nuspojave su većinom blage ili umjerene.
English: Reagila cariprazine
Croatian: Reagila kariprazin
English: Because the medicine's effects may take time to show, patients should be monitored for several weeks after starting treatment or changing the dose.
Croatian: Budući da se učinci lijeka mogu pokazati tek nakon nekog vremena, bolesnike treba promatrati nekoliko tjedana nakon početka liječenja ili nakon promjene doze.
English: This reduces symptoms of schizophrenia and prevents them from returning.
Croatian: Time se smanjuju simptomi shizofrenije i sprečava se njihov povratak.
English: What is Reagila and what is it used for?
Croatian: Što je Reagila i za što se koristi?
English: Reagila must not be taken at the same time as certain other medicines called strong or moderate CYP3A4 inhibitors or inducers.
Croatian: Lijek Reagila ne smije se primjenjivati istodobno s određenim drugim lijekovima koji se nazivaju jakim ili umjerenim CYP3A4 inhibitorima ili induktorima.
English: This is a summary of the European public assessment report (EPAR) for Reagila.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Reagila.
English: Reagila is an antipsychotic medicine used to treat schizophrenia in adults.
Croatian: Reagila je antipsihotički lijek koji se koristi za liječenje shizofrenije u odraslih.
English: Reagila is available as capsules (1.5, 3, 4.5 and 6 mg) to be taken by mouth.
Croatian: Lijek Reagila dostupan je u obliku kapsula (1,5 mg, 3 mg, 4,5 mg i 6 mg) koje se uzimaju kroz usta.
English: Since dopamine and serotonin play a role in schizophrenia, by attaching to their receptors, cariprazine helps normalise the activity of the brain.
Croatian: Budući da dopamin i serotonin imaju ulogu u shizofreniji, vezivanjem na njihove receptore kariprazin pomaže normalizirati aktivnost mozga.
English: Other information about Reagila
Croatian: Ostale informacije o lijeku Reagila
English: What measures are being taken to ensure the safe and effective use of Reagila?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Reagila?
English: Therefore, the European Medicines Agency decided that Reagila's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Stoga je Europska agencija za lijekove zaključila da koristi od lijeka Reagila nadmašuju s njim povezane rizike i preporučila davanje odobrenja za njegovu primjenu u EU-u.
English: The dose can be increased by 1.5 mg at a time up to a maximum of 6 mg per day.
Croatian: Doza se može povećati za 1,5 mg u jednom navratu do najveće doze od 6 mg na dan.
English: Schizophrenia is a mental illness with symptoms such as delusions, disorganised thinking and speech, suspiciousness and hallucinations (hearing or seeing things that are not there).
Croatian: Shizofrenija je mentalna bolest koja se očituje simptomima kao što su deluzije, nesuvislo razmišljanje i govor, sumnjičavost i halucinacije (bolesnici čuju ili vide nešto čega nema).
English: The lowest dose that works well for the patient should be maintained.
Croatian: Trebalo bi održati najmanju dozu koja ima djelotvoran učinak na bolesnika trebala.
English: It is not intended to provide practical advice on how to use Reagila.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Reagila.
English: Over a 72 week period, symptoms returned in a quarter of patients taking Reagila compared with around half of those taking placebo.
Croatian: U razdoblju od 72 tjedna simptomi su se vratili kod četvrtine bolesnika koji su uzimali lijek Reagila u usporedbi s polovinom bolesnika koji su uzimali placebo.
English: A fourth main study in 461 patients who mostly had ‘negative' symptoms (such as lack of drive, social withdrawal, and problems with attention and memory) and only few ‘positive' symptoms (such as delusions and hallucinations) showed that Reagila was effective at treating negative symptoms: after 26 weeks of treatment Reagila lowered the PANSS score for negative symptoms by around 9 points compared with around 7 points with another medicine, risperidone.
Croatian: Četvrto glavno ispitivanje provedeno na 461 bolesnikom koji su uglavnom imali „negativne” simptome (kao što su manjak energije, društvena povučenost i problemi s pažnjom i pamćenjem) te samo nekoliko „pozitivnih” simptoma (kao što su deluzije i halucinacije) pokazalo je da je lijek Reagila djelotvoran kod liječenja negativnih simptoma: nakon 26 tjedana liječenja lijekom Reagila rezultat na PANSS ljestvici za negativne simptome smanjio se za oko 9 bodova u usporedbi s drugim lijekom, risperidonom, kod kojeg se rezultat smanjio za oko 7 bodova.
English: The active substance in Reagila, cariprazine, attaches to receptors (targets) in the brain for two neurotransmitters called dopamine and serotonin, which nerve cells use to communicate with neighbouring cells.
Croatian: Djelatna tvar u lijeku Reagila, kariprazin, veže se u mozgu na receptore (mete) dvaju neurotransmitera koji se nazivaju dopamin i serotonin, a koje živčane stanice koriste za komunikaciju sa susjednim stanicama.
English: As well as studies showing that Reagila improves the positive symptoms of schizophrenia both in the short and longer term, one study also showed that the medicine improved the negative symptoms of the disease which have a large impact on patients' quality of life.
Croatian: Slično ispitivanjima koja su pokazala da lijek Reagila kratkoročno i dugoročno poboljšava pozitivne simptome shizofrenije, jedno je ispitivanje pokazalo da lijek poboljšava i negativne simptome bolesti koji imaju velik učinak na kvalitetu života bolesnika.